20.33
+1.30%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Denali Therapeutics
From its filings with the US Securities and Exchange Commission
Denali Therapeutics is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DNLI. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $512.5m. At that date it held total assets of $1.14bn and shareholders' equity of $1.01bn.
Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering medicines for people living with serious diseases.
Historically, the blood-brain barrier has been a major challenge to the development of medicines for diseases of the central nervous system. While the blood-brain barrier protects the brain and is essential for our survival, it also prevents the delivery of medicines to the brain in sufficient quantities to have therapeutic effect. We have invented, developed, and validated a proprietary technology, called the TransportVehicleTM ("TV"), to address the blood-brain barrier challenge and enable a new class of barrier-crossing therapeutics. The TV has a modular design enabling delivery of large molecules, i.e., enzymes, oligonucleotides, and antibodies, to all tissues of the body, including the brain, by crossing the blood-brain barrier after systemic administration. Over the last few decades, large molecule biotherapeutics have enabled medical breakthroughs in treating a wide array of serious diseases, but with very limited success in central nervous system diseases. Now, with the invention and validation of our TV technology, we are leading the field in delivering on the potential of biotherapeutics to transform the lives of individuals with neurodegenerative diseases, lysosomal storage disorders, and other serious diseases.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Dec 2017
- Employees
- 503
- Website
- denalitherapeutics.com ↗
- Head office
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Julian BakerIndependent Chairman of the Board
- Dr. Ryan WattsPresident, Chief Executive Officer, Director, since 2015$6.6m
- Dr. Alexander SchuthChief Operating and Financial Officer, Secretary, since 2022$4.0m
- Dr. Peter ChinActing Chief Medical Officer, Head - Development
- Mr. Steven KrognesDirector$359,465
- Mr. Tim van HauwermeirenDirector
- Ms. Jennifer CookIndependent Director$369,465
- Mr. Jay FlatleyIndependent Director, since 2015$384,465
- Mr. Peter KleinIndependent Director$389,431
- Dr. David SchenkeinIndependent Director$379,465
- Dr. Marc Tessier-LavignecIndependent Director, since 2015$371,965
- Ms. Nancy ThornberryIndependent Director$374,465
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 82
- Environment
- 93
- Social
- 99
- Governance
- 53
- Women in the workforce
- 54%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Denali Therapeutics Inc has developed a robust pipeline of innovative therapeutic candidates targeting various neurological diseases. This diverse portfolio positions the company well to address multiple unmet medical needs and capture a significant market share in the neurodegenerative diseases space.
- The company is led by a highly experienced management team with a proven track record in the biotechnology industry. Their expertise in drug development, commercialization, and strategic partnerships provides Denali Therapeutics with strong leadership and guidance for achieving its objectives.
Weaknesses
- Denali Therapeutics relies heavily on external collaborations for the development and commercialization of its therapeutic candidates. While partnerships can bring valuable resources and expertise, they also pose a risk of delays, conflicts of interest, and potential limitations in the company's control over its own products.
- As a relatively young company, Denali Therapeutics has limited experience in the commercialization of pharmaceutical products. Successfully bringing candidates to market and navigating the complex regulatory and market access landscape can be challenging, requiring additional resources and expertise in marketing, distribution, and pricing strategies.
Opportunities
- The prevalence of neurodegenerative diseases, such as Alzheimer's and Parkinson's, is increasing globally. This presents a significant market opportunity for Denali Therapeutics to address the growing demand for effective treatments. By leveraging its pipeline and focusing on targeted therapies, the company can tap into this expanding market.
- Advancements in genetic research have provided deeper insights into the underlying causes of neurodegenerative diseases. Denali Therapeutics can capitalize on these discoveries by developing therapies that target specific genetic mutations or dysfunctions, potentially offering personalized medicine solutions and differentiation from competitors.
Threats
- The biotechnology industry is highly competitive, with numerous companies competing for limited market share and investment. Denali Therapeutics faces the risk of intense competition from both established pharmaceutical companies and emerging biotech startups, which may have similar development programs and resources.
- The regulatory approval process for pharmaceutical products, especially in the field of neurodegenerative diseases, can be complex and time-consuming. Delays or failures to obtain regulatory approvals could significantly impact Denali Therapeutics' ability to bring its therapies to market. In addition, reimbursement challenges and pricing pressures may affect the commercial success and accessibility of the company's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.